A novel vaccine platform using glucan particles for induction of protective responses against Francisella tularensis and other pathogens

Clin Exp Immunol. 2019 Nov;198(2):143-152. doi: 10.1111/cei.13356. Epub 2019 Sep 12.

Abstract

Vaccines are considered the bedrock of preventive medicine. However, for many pathogens, it has been challenging to develop vaccines that stimulate protective, long-lasting immunity. We have developed a novel approach using β-1,3-D-glucans (BGs), natural polysaccharides abundantly present in fungal cell walls, as a biomaterial platform for vaccine delivery. BGs simultaneously provide for receptor-targeted antigen delivery to specialized antigen-presenting cells together with adjuvant properties to stimulate antigen-specific and trained non-specific immune responses. This review focuses on various approaches of using BG particles (GPs) to develop bacterial and fungal vaccine candidates. A special case history for the development of an effective GP tularaemia vaccine candidate is highlighted.

Keywords: beta-glucans; fungal; tularemia; vaccine.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Adjuvants, Immunologic / therapeutic use*
  • Animals
  • Bacterial Vaccines* / immunology
  • Bacterial Vaccines* / therapeutic use
  • Drug Delivery Systems*
  • Francisella tularensis / immunology*
  • Glucans / therapeutic use*
  • Humans
  • Tularemia* / immunology
  • Tularemia* / prevention & control
  • Vaccination

Substances

  • Adjuvants, Immunologic
  • Bacterial Vaccines
  • Glucans